Risk of Cardiovascular Events in a Real-World Population of 86,564 Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitor Therapy

Authors: E. J. Stanek, N. J. Markward, B. C. Agatep, S. L. Charland

In a diverse population on clopidogrel; 1-yr major adverse CV event (MACE) risk was significantly increased with concurrent PPI use overall, and by esomeprazole, omeprazole, pantoprazole, and lansoprazole individually. Rabeprazole use was risk-neutral, and further evaluation of dexlansoprazole in a larger sample is warranted. Overall hospitalization for upper GI bleeding was low. These findings extend evidence of a clopidogrel-PPI interaction into a general population with a widerange of indications for antiplatelet therapy.

Citation: Clinical Pharmacology & Therapeutics (2011) 89, S8–S9.

Link: http://www.nature.com/clpt/journal/v89/n1s/abs/clpt2010328a.html